Pediatric Depression
- Author: Angelo P Giardino, MD, PhD, MPH; Chief Editor: Caroly Pataki, MD more...
Background
Pediatric depression in the form of childhood and adolescent major depressive disorder (MDD) is a relatively common psychiatric condition that generally continues episodically into adulthood.
Childhood depression seems to be evident at earlier ages in successive cohorts and often occurs with comorbid psychiatric disorders, increased risk for suicide, substance abuse, and behavior problems. Children and adolescents with depression frequently have poor psychosocial, academic, and family functioning. (See Etiology.)
Whether ego-damaging experiences or biologic processes cause depression remains the topic of some debate. The final common pathways to depression involve biochemical changes in the brain. (See Pathophysiology and Etiology.)
The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), uses the same basic criteria to diagnose depression in adults and children. A few small adjustments were made to the diagnostic criteria to account for the differences in age and stage of development in adults and children. (See Presentation.)
The choice of initial acute therapy depends on the following factors:
- Severity
- Number of prior episodes
- Chronicity
- Subtype
- Patient age
- Contextual issues - Eg, family conflict, academic problems, exposure to negative life events
- Compliance with treatment
- Previous response to treatment
- Patient's and family’s motivation for treatment
In mild cases, psychosocial interventions are often recommended as first-line treatments, whereas, in the most severe cases, medication in addition to psychotherapeutic intervention is often recommended. (See Treatment.)
Cognitive-behavioral therapy (CBT) has been shown in multiple randomized, clinical trials to be effective in the treatment of mild to moderate MDDs in children and adolescents. While psychopharmacologic treatment alone is not recommended, in severe cases it may add benefit. Hospitalization should be considered for severely affected patients for whom an effective safety plan and supervision are not feasible and for those patients and families unable or unlikely to comply with treatment recommendations.[1, 2] (See Treatment and Medication.)
Go to Depression for complete information on this topic.
Pathophysiology
Brain abnormalities
Several areas of the brain are involved in mood functions. Sleep, appetite, and memory are commonly disturbed in persons with depression. Except for the pituitary, all cerebral components responsible for these functions are broadly considered to be a part of the limbic system; all components normally receive signals from neurons that secrete serotonin or norepinephrine or from neurons of both types. Reductions in the activity of circuits that use serotonin and norepinephrine are thought to contribute to depression.
One abnormality that was discovered in an area of the brain that helps to control emotional reactions has contributed to a new understanding of why persons develop depression and other affective disturbances. Using positron emission tomographic (PET) scanning, researchers found an area of the prefrontal cortex with abnormally diminished activity in patients with unipolar depression and bipolar depression.[3] This region is related to emotional response and has widespread connections with other areas of the brain.
These other areas of the brain are responsible for the regulation of dopamine, noradrenaline, and serotonin, which have important roles in the regulation of mood. PET imaging provides the means for the study of receptor volume and the effect a compound may have on receptors; however, PET is problematic for use with children and adolescents because it requires complex equipment and uses radiation.
Magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and magnetoencephalography (MEG) are best suited to study the structural, physiologic, and developmental brain abnormalities in youths because they do not involve ionizing radiation or radioactive isotopes. To date, few neuroimaging studies have been performed in depressed youths.[4]
Steingard et al, in a study using MRI to compare 65 latency-aged children and adolescents who were hospitalized with depression with 18 hospitalized psychiatric controls who did not have a depressive disorder, found that depressed youths had a significantly smaller ratio of frontal lobe volume to total cerebral volume and a significantly larger ratio of lateral ventricular volume to total cerebral volume.[5] The researchers suggested that these alterations in cerebral volumes may signal a role for the frontal lobes in the development of early onset depression.
Tutus et al, in a study involving 14 adolescent outpatients (aged 11-15 y) with MDD and 11 age-matched controls, found significant differences between the perfusion index values of untreated depressed patients and those of the controls. The adolescents were observed by means of single-photon emission computed tomography (SPECT) scanning in order to examine cerebral perfusion and any association between perfusion indices and clinical variables.[6]
These differences in perfusion index values were indicative of relatively reduced perfusion in the left anterofrontal and left temporal cortical areas. The investigators suggested that adolescents with MDD may have regional blood flow deficits in left anterofrontal and left temporal cortical regions, with greater right-left perfusion asymmetry than healthy controls have.
Neuroendocrine abnormalities
De Bellis et al, in a study examining nocturnal secretion of adrenocorticotropin (ACTH), cortisol, growth hormone (GH), and prolactin in a group of prepubertal children who were depressed and a control group, reported that prepubertal children who were depressed had lower cortisol secretion during the first 4 hours of sleep than did children in the control group.[7] ACTH, GH, and prolactin secretion did not differ between the 2 groups.
Possible neurotransmitter system abnormalities are under investigation. Nobile et al found that human platelet 5-hydroxytryptamine (5-HT; serotonin) uptake is differentially influenced in nondepressed and depressed children by a common genetic variant of the promoter region of 5-HTT.[8]
Birmaher et al found that before the onset of affective illness, high-risk children had the same pattern of neuroendocrine response to 5-hydroxy-L-tryptophan (L-5-HTP) challenge as did children with MDD.[9] These findings could lead to identification of a trait marker for pediatric depression.
Etiology
Biologic versus nonbiologic causes
Whether ego-damaging experiences or biological processes cause depression remains the topic of some debate. The final common pathways to depression involve biochemical changes in the brain. (See Pathophysiology.)
Genetic factors
Several studies of adults who are depressed, such as those reported by Akiskal and Weller[10] and Weissman et al[11] suggest a genetic component in the etiology of depressive disorders.
Parent-child relation model
The parent-child relation model conceptualizes pediatric depression as the result of poor parent-child interaction. Adults with depression report low paternal involvement and high maternal overprotection during early childhood. Troubled relationships with parents, siblings, and peers are common in children and adolescents with affective illness.[12] A child who is affectively ill often has a parent who is affectively ill. It is not uncommon for children to report abuse and/or neglect by the parent or parents who are affectively ill.
Hammen et al reported a significant temporal association between mother and child.[13] They found that children with substantial stress exposure who also had a symptomatic mother were significantly more depressed than children who were exposed to comparable levels of stress only.
Cohort effect
Klerman and Gershon reported a progressive increase in the lifetime cases of major depression over the last 70 years. They found high rates of affective disorders among relatives, with a younger age of onset in successive cohorts.[14]
Epidemiology
Occurrence in the United States
Reported US prevalence rates for depression in children and adolescents vary. Differences may be due to different populations sampled and variable criteria used. Studies have demonstrated that the occurrence of depression is not rare and is encountered regularly in pediatric and psychiatric practice.
Kashani and Sherman conducted epidemiologic studies in the United States that revealed the incidence of depression to be 0.9% in preschool-aged children, 1.9% in school-aged children, and 4.7% in adolescents.[15] Garrison et al conducted a study of adolescents aged 11-16 years in the southeastern United States and found that the 1-year incidence of major depression was 3.3%.[16]
International occurrence
Available data on the international incidence of major depression in children and adolescents are sparse. Reported adult prevalence rates generally mirror those of the United States.
Helgason examined the entire Icelandic birth cohort of 1895-97 with periodic follow-up until cohort individuals reached age 74-76 years. The lifetime estimates of risk for any affective disorder were 14.8% for females and 9.8% for males.[17]
In 2000, Murphy et al, using data from the Stirling County Study of adults in Atlantic Canada, found that the overall prevalence of depression remained stable at 5% across 3 separate samples in 1952, 1970, and 1992.[18] The investigators also reported a redistribution in the most recent sample, indicating that prevalence had shifted from older to younger persons and that the female-to-male ratio had increased. The Stirling County Study, which began shortly after World War II, offered a 40-year perspective of the prevalence and incidence of psychiatric disorders among an adult population in Atlantic Canada.
A European study by Copeland et al, which sought to assess the prevalence of depression in 9 European nations in order to design intervention for elderly persons who were depressed, found widely ranging prevalences in the study centers.[19] Prevalence for females was higher than for males. There was no constant association between prevalence and age. Meta-analysis revealed an overall prevalence of 12.3% and sex frequencies of 14.1% for females and 8.6% for males.
According to Jablensky, the World Health Organization (WHO) collaborative study on the assessment of depressive disorders examined depressive patients in Canada, Iran, Japan, and Switzerland and found considerable similarity in depressive symptomatology across cultures.[20]
Age-related demographics
Evidence suggests that the presentation of some symptoms may change with age. Symptoms such as somatic complaints, irritability, and social withdrawal are more common in children, whereas psychomotor retardation, hypersomnia, and delusions are less common prior to puberty than they are in adolescence and adulthood.[21, 22, 23, 24]
Sex-related demographics
Hankin et al conducted a prospective, 10-year, longitudinal study of preadolescents through young adulthood and found that the most critical time for sex differences to emerge is the period when adolescents are aged 15-18 years.[25]
During this period, the increase of the overall rates of depression and the onset of new cases of depression peak. The rates of depression increase dramatically for both sexes, and the rate of depression in females grows to twice the prevalence rate for males. No sex differences are noted for depression symptom severity or recurrence.
A study of a randomly selected sample of high school students revealed that 22.3% of females and 11.4% of male high school students reported 1 current or lifetime episode of unipolar depression.[15] The percentage of male and female students with 2 or more episodes was 4.9% and 1.6%, respectively.[16]
Race-related demographics
Cultural norms associated with differing racial and ethnic groups can affect the experience and reporting of symptoms of depression. In some cultures, for example, depression may be experienced largely in somatic terms, in place of sadness or guilt. Several studies point toward the role of culture in childhood and adolescent depression. For example, the stress of acculturation was found to have a role in the increased incidence of depressive symptoms and suicidal ideation among Hispanic youths.[26]
In an epidemiologic study of youths aged 12-17 years in Los Angeles County in 1998, Siegel et al found that Hispanic youths reported more symptoms of depression, independent of socioeconomic status, when compared with white, African American, or Asian American adolescents, using the Children’s Depression Inventory (CDI).[27] This study also found significant effects of social class on depression. As income decreased, the average level of depression increased.
More extensive studies of ethnic subpopulations of adolescents who are depressed are needed. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), states that a symptom should not be dismissed because it is part of a cultural norm.[28] Likewise, culturally distinctive experiences (eg, fear of being hexed or bewitched; experience of visitations from the dead) should be distinguished from actual hallucinations or delusions that may be part of a major depressive episode with psychotic features.
Prognosis
Risk of future depression
According to the American Academy of Child and Adolescent Psychiatry, practice parameters for depressive disorders in childhood and adolescence, a history of a previous depressive episode, subsyndromal symptoms of depression, dysthymia, and anxiety disorders increase the risk for future depression.[29]
In a study of an epidemiologic sample of 776 adolescents, Pine and associates found that symptoms of major depression in adolescence strongly predicted adult episodes of major depression.[30]
Risk of suicide
As many as 15% of persons with depression or bipolar disorder commit suicide each year. In 1996, the Centers for Disease Control and Prevention (CDC) listed suicide as the ninth leading cause of death in the United States, accounting for 30,862 deaths. Many believe this number is a gross underestimate. For example, children’s deaths are often ruled as accidental when the intent of the deceased is not apparent. The feasibility of suicide among children is frequently unthinkable, even to health professionals.
Because mood disorders, such as depression, substantially increase the risk of suicide, suicidal behavior is a matter of serious concern for clinicians who deal with the mental health problems of children and adolescents. The incidence of suicide attempts reaches a peak during the midadolescent years, and the mortality rate from suicide increases steadily through the teenage years, with suicide being the third leading cause of death in that age group.
Risk factors for completed suicide include the presence of a major mood disorder, occurrence of command auditory hallucinations, use of substances, and evidence of specific plans and an attempt to prevent discovery, as well as patient perception of failure of the issues that precipitated suicidal thinking to change. This lack of action tends to escalate the patients’ sense of hopelessness.
The Clinical Trial Registration Information–Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study noted that a history of nonsuicidal self injury (NSSI) can be predictive of future NSSI and suicide attempts in adolescents with treatment-resistant depression.[31]
Another study noted a significant NSSI rate (3,000 in 10,000) among Native American youths aged 10-14 years, specifically the White Mountain Apache tribe. Females reported a higher rate of NSSI than males; severe substance abuse was also noted among both boys and girls. While NSSI is largely unaddressed among the White Mountain Apache Tribe and likely other reservation communities, it is important to recognize that this mental health issue could serve as a precursor to suicide in this population.[32]
Patient Education
Educating parents about children’s emotional problems is very important. Education is known to result in better compliance with treatment and to improve parents’ understanding toward their children. Patients should be educated in a manner congruent with individual development, level of impairment, and clinician judgment.
The clinician should instruct parents and others in the homes of depressed youths to remove firearms from their homes to decrease the risk of suicide. Household medications also should not be accessible to depressed youths.
For patient education resources, see the Depression Center, as well as Depression, Substance Abuse, and Antidepressant Medications.
Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry. Nov 1996;35(11):1427-39. [Medline].
Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry. Dec 1996;35(12):1575-83. [Medline].
Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. Apr 24 1997;386(6627):824-7. [Medline].
Hendren RL, De Backer I, Pandina GJ. Review of neuroimaging studies of child and adolescent psychiatric disorders from the past 10 years. J Am Acad Child Adolesc Psychiatry. Jul 2000;39(7):815-28. [Medline].
Steingard RJ, Renshaw PF, Yurgelun-Todd D, et al. Structural abnormalities in brain magnetic resonance images of depressed children. J Am Acad Child Adolesc Psychiatry. Mar 1996;35(3):307-11. [Medline].
Tutus A, Kibar M, Sofuoglu S, et al. A technetium-99m hexamethylpropylene amine oxime brain single-photon emission tomography study in adolescent patients with major depressive disorder. Eur J Nucl Med. Jun 1998;25(6):601-6. [Medline].
De Bellis MD, Dahl RE, Perel JM, et al. Nocturnal ACTH, cortisol, growth hormone, and prolactin secretion in prepubertal depression. J Am Acad Child Adolesc Psychiatry. Sep 1996;35(9):1130-8. [Medline].
Nobile M, Begni B, Giorda R, et al. Effects of serotonin transporter promoter genotype on platelet serotonin transporter functionality in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. Nov 1999;38(11):1396-402. [Medline].
Birmaher B, Kaufman J, Brent DA, et al. Neuroendocrine response to 5-hydroxy-L-tryptophan in prepubertal children at high risk of major depressive disorder. Arch Gen Psychiatry. Dec 1997;54(12):1113-9. [Medline].
Akiskal HS, Weller ES. Mood disorders and suicide in children and adolescents. In: Kaplan HI, Saddock BJ, eds. Comprehensive Textbook of Psychiatry. Vol 2. 5th ed. Lippincott Williams & Wilkins; 1989.
Weissman MM, Leckman JF, Merikangas KR, et al. Depression and anxiety disorders in parents and children. Results from the Yale family study. Arch Gen Psychiatry. Sep 1984;41(9):845-52. [Medline].
Bang KS, Chae SM, Hyun MS, et al. The mediating effects of perceived parental teasing on relations of body mass index to depression and self-perception of physical appearance and global self-worth in children. J Adv Nurs. Mar 4 2012;[Medline].
Hammen C, Burge D, Adrian C. Timing of mother and child depression in a longitudinal study of children at risk. J Consult Clin Psychol. Apr 1991;59(2):341-5. [Medline].
Klerman GL, Weissman MM. Increasing rates of depression. JAMA. Apr 21 1989;261(15):2229-35. [Medline].
Kashani JH, Sherman DD. Childhood depression: Epidemiology, etiological models, and treatment implications. Integr Psychiatry. 1988;6:1-8.
Garrison CZ, Waller JL, Cuffe SP, et al. Incidence of major depressive disorder and dysthymia in young adolescents. J Am Acad Child Adolesc Psychiatry. Apr 1997;36(4):458-65. [Medline].
Helgason T. Epidemiology of psychiatric disorders in Iceland. Nord J Psychiatry. 1996;50:31-8.
Murphy JM, Laird NM, Monson RR, et al. Incidence of depression in the Stirling County Study: historical and comparative perspectives. Psychol Med. May 2000;30(3):505-14. [Medline].
Copeland JR, Beekman AT, Dewey ME, et al. Depression in Europe. Geographical distribution among older people. Br J Psychiatry. Apr 1999;174:312-21. [Medline].
Jablensky A, Sartorius N, Gulbinat W, Ernberg G. Characteristics of depressive patients contacting psychiatric services in four cultures. A report from the who collaborative study on the assessment of depressive disorders. Acta Psychiatr Scand. Apr 1981;63(4):367-83. [Medline].
Kovacs M, Gatsonis C. Secular trends in age at onset of major depressive disorder in a clinical sample of children. J Psychiatr Res. May-Jun 1994;28(3):319-29. [Medline].
Lewinsohn PM, Clarke GN, Seeley JR, Rhode P. Major depression in community adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry. Jul-Aug 1994;33(6):809-18. [Medline].
Lewinsohn PM, Hops H, Roberts RE, et al. Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol. Feb 1993;102(1):133-44. [Medline].
Lewinsohn PM, Rohde P, Klein DN, Seeley JR. Natural course of adolescent major depressive disorder: I. Continuity into young adulthood. J Am Acad Child Adolesc Psychiatry. Jan 1999;38(1):56-63. [Medline].
Hankin BL, Abramson LY, Moffitt TE, et al. Development of depression from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study. J Abnorm Psychol. Feb 1998;107(1):128-40. [Medline].
Hovey JD, King CA. Acculturative stress, depression, and suicidal ideation among immigrant and second-generation Latino adolescents. J Am Acad Child Adolesc Psychiatry. Sep 1996;35(9):1183-92. [Medline].
Siegel JM, Aneshensel CS, Taub B. Adolescent depressed mood in a multiethnic sample. J Youth Adolesc. 1998;27.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM- IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.
AACAP. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. AACAP. J Am Acad Child Adolesc Psychiatry. Oct 1998;37(10 Suppl):63S-83S. [Medline].
Pine DS, Cohen E, Cohen P, Brook J. Adolescent depressive symptoms as predictors of adult depression: moodiness or mood disorder?. Am J Psychiatry. Jan 1999;156(1):133-5. [Medline]. [Full Text].
Asarnow JR, Porta G, Spirito A, et al. Suicide Attempts and Nonsuicidal Self-Injury in the Treatment of Resistant Depression in Adolescents: Findings from the TORDIA Study. J Am Acad Child Adolesc Psychiatry. Aug 2011;50(8):772-81. [Medline]. [Full Text].
Cwik MF, Barlow A, Tingey L, Larzelere-Hinton F, Goklish N, Walkup JT. Nonsuicidal self-injury in an american Indian reservation community: results from the white mountain apache surveillance system, 2007-2008. J Am Acad Child Adolesc Psychiatry. Sep 2011;50(9):860-9. [Medline].
Wickramaratne PJ, Greenwald S, Weissman MM. Psychiatric disorders in the relatives of probands with prepubertal- onset or adolescent-onset major depression. J Am Acad Child Adolesc Psychiatry. Nov 2000;39(11):1396-405. [Medline].
Hooshmand S, Willoughby T, Good M. Does the direction of effects in the association between depressive symptoms and health-risk behaviors differ by behavior? A longitudinal study across the high school years. J Adolesc Health. Feb 2012;50(2):140-7. [Medline].
Weller EB, Weller RA, Fristad MA, et al. The dexamethasone suppression test in prepubertal depressed children. J Clin Psychiatry. Dec 1985;46(12):511-3. [Medline].
Strober M, DeAntonio M, Schmidt-Lackner S, et al. The pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls. J Clin Psychiatry. Mar 1999;60(3):164-9. [Medline].
Ambrosini PJ, Wagner KD, Biederman J, et al. Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry. May 1999;38(5):566-72. [Medline].
Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. Aug 27 2003;290(8):1033-41. [Medline].
Birmaher B, Brent DA, Kolko D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry. Jan 2000;57(1):29-36. [Medline].
Brent DA, Kolko DJ, Birmaher B, et al. Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry. Sep 1998;37(9):906-14. [Medline].
Merry SN, Hetrick SE, Cox GR, Brudevold-Iversen T, Bir JJ, McDowell H. Psychological and educational interventions for preventing depression in children and adolescents. Cochrane Database Syst Rev. Dec 7 2011;12:CD003380. [Medline].
Mihalopoulos C, Vos T, Pirkis J, et al. The population cost-effectiveness of interventions designed to prevent childhood depression. Pediatrics. Mar 2012;129(3):e723-30. [Medline].
Clarke GN, Rohde P, Lewinsohn PM, et al. Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry. Mar 1999;38(3):272-9. [Medline].
Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. Jan 2006;26(1):17-31. [Medline].
Kroll L, Harrington R, Jayson D, et al. Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients. J Am Acad Child Adolesc Psychiatry. Sep 1996;35(9):1156-61. [Medline].
[Best Evidence] Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, et al. Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA. Jun 3 2009;301(21):2215-24. [Medline].
Mufson L, Fairbanks J. Interpersonal psychotherapy for depressed adolescents: a one-year naturalistic follow-up study. J Am Acad Child Adolesc Psychiatry. Sep 1996;35(9):1145-55. [Medline].
Barclay L. Efficacy of Antidepressant Medication vs Placebo Increases With Severity of Depression. Medscape Today. Available at http://www.medscape.com/viewarticle/715585. Accessed February 4, 2010.
Fournier JC, DeRubeis RJ, Hollon ST, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. Available at http://jama.ama-assn.org/content/303/1/47.full. Accessed February 4, 2010.
Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 7th ed. Hudson, Ohio: Lexi-Comp, Inc; 2000.
Leonard HL, March J, Rickler KC, Allen AJ. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry. Jun 1997;36(6):725-36. [Medline].
Rey-Sanchez F, Gutierrez-Casares JR. Paroxetine in children with major depressive disorder: an open trial. J Am Acad Child Adolesc Psychiatry. Oct 1997;36(10):1443-7. [Medline].
Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. Nov 1997;54(11):1031-7. [Medline].
Shamseddeen W, Clarke G, Wagner KD, et al. Treatment-Resistant Depressed Youth Show a Higher Response Rate if Treatment Ends During Summer School Break. J Am Acad Child Adolesc Psychiatry. Nov 2011;50(11):1140-8. [Medline].
King RA, Segman RH, Anderson GM. Serotonin and suicidality: the impact of acute fluoxetine administration. I: Serotonin and suicide. Isr J Psychiatry Relat Sci. 1994;31(4):271-9. [Medline].
Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf. Mar 1993;8(3):186-212. [Medline].
Newman TB. A black-box warning for antidepressants in children?. N Engl J Med. Oct 14 2004;351(16):1595-8. [Medline].
Kurian BT, Ray WA, Arbogast PG, et al. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med. Jul 2007;161(7):690-6. [Medline].
Cassels C. FDA Suicide Warnings Change Antidepressant Prescribing Patterns, but Physicians Ignore Monitoring Recommendations. Medscape Today. Available at http://www.medscape.com/viewarticle/715952. Accessed February 4, 2010.
Cassels C. FDA Suicide Warnings About Antidepressants Cut Rates of Depression Diagnosis and Treatment. Medscape Today. Available at http://www.medscape.com/viewarticle/704235. Accessed February 4, 2010.
Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. Oct-Nov 2001;10(6):525-30. [Medline].
Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ. May 10 2003;326(7397):1008. [Medline]. [Full Text].
Olfson M, Marcus SC, Druss B, Pincus HA. National trends in the use of outpatient psychotherapy. Am J Psychiatry. Nov 2002;159(11):1914-20. [Medline]. [Full Text].
March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. Aug 18 2004;292(7):807-20. [Medline].
Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. Jan 2006;163(1):41-7. [Medline]. [Full Text].
Daly JM, Wilens T. The use of tricyclic antidepressants in children and adolescents. Pediatr Clin North Am. Oct 1998;45(5):1123-35. [Medline].
Geller B, Reising D, Leonard HL, et al. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry. May 1999;38(5):513-6. [Medline].
Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ. Apr 8 1995;310(6984):897-901. [Medline].

